2/26/2021 6:57:44 AM
CHMP Adopts Positive Opinion For Evrysdi For Spinal Muscular Atrophy In Adults And Children Aged Two Months And Older
2/17/2021 8:28:34 AM
PTC Therapeutics Initiates Second Stage Of FITE19 Phase 2/3 Clinical Trial Evaluating PTC299 For COVID-19
12/4/2020 8:04:25 AM
PTC Announces Translarna Approval In Russia For Treatment Of Duchenne Muscular Dystrophy
11/30/2020 8:21:05 AM
PTC Therapeutics Initiates Global Phase 3 Clinical Trial To Evaluate Vatiquinone In Friedreich Ataxia
11/17/2020 8:07:37 AM
PTC Therapeutics Says PTC518 Enters Into Phase 1 Trial For Huntington's Disease Program
10/26/2020 8:19:06 AM
PTC Therapeutics Begins Registration-Directed Clinical Trial To Evaluate Vatiquinone In Mitochondrial Epilepsy
8/17/2020 8:11:05 AM
PTC : EU Accepts Marketing Authorization Application For Evrysdi For Treatment Of Spinal Muscular Atrophy
7/20/2020 7:35:49 AM
PTC Therapeutics Announces Deal To Monetize Portion Of Risdiplam Royalty Stream For $650 Mln From Royalty Pharma
7/8/2020 8:15:34 AM
PTC Therapeutics Reports First Patient Dosed In Phase 1 Trial For PTC857
6/29/2020 8:23:06 AM
PTC Therapeutics Announces CHMP Recommendation Of Translarna Label Update For Non-Ambulatory Patients With DMD
6/17/2020 6:31:45 AM
PTC Therapeutics Begins Phase 2/3 Clinical Trial To Evaluate PTC299 For COVID-19
6/1/2020 8:01:35 AM
PTC Therapeutics Completes Acquisition Of Censa Pharmaceuticals
4/28/2020 1:15:26 AM
PTC Therapeutics Reports Positive Results From Part 2 Of The Pivotal FIREFISH Study Evaluating Risdiplam
4/17/2020 8:04:33 AM
PTC Therapeutics Names Matthew Klein Chief Development Officer And Eric Pauwels To Chief Business Officer